

CURRICULUM VITAE

Roxana Voica, MD

EDUCATION:

Medical Doctor Degree – 1989 – University of Medicine, Bucharest, Romania

SPECIALITY TRAINING:

**Allergy – Immunology Fellowship – 07/1995 – 06/1997 – Wayne State University
Detroit, Michigan**

**Internal Medicine Residency - 04/1992– 06/1995 - Oakwood Hospital Dearborn,
Michigan and Meridia Huron
Hospital/Cleveland Clinic,
Cleveland, Ohio**

CERTIFICATION:

**American Board of Allergy and Immunology – 1997 – Recertified 2007 & 2017
American Board of Internal Medicine – 1995**

PROFESSIONAL EXPERIENCE:

**Allergy Immunology Practice – 1/98 – Present – Topeka Allergy & Asthma Clinic
Topeka, KS**

PROFESSIONAL APPOINTMENTS:

Fellow - American College of Asthma, Allergy and Immunology

Member - American Academy of Allergy and Immunology

Member - Kansas Foundation for Medical Care

Member – Greater Kansas City Allergy Society

RESEARCH :

R. Voica, D. Colita: T-Cell Lymphomas – Clinical and Immunophenotypical study. Oral presentation at the Medical Students Scientific Session, Bucharest, Romania, 1989.

R. Voica, N. Lekas, R. Kiel: Primary Cardiac Tumors – An Experience at Oakwood Hospital, oral presentation at the American College of Physicians 39th Michigan Scientific Meeting, Traverse City, Michigan, 1993.

R. Voica, M.R. Simon, H. Chin: Skin test Reactivity to Sulbactam: The first Reported Case. Poster presentation, ACAAI, Boston, 1996.

R. Voica, K. Konduri: Incontinentia Pigmenti as a Cause of Rash and Eosinophilia. Poster presentation, ACAAI, Boston, 1996.

Subinvestigator – Prospective, Uncontrolled, Non-Blind Clinical Trial of the Safety and Efficacy of Bay 12-8039 400 MG PO QD in the Treatment of Patients with Acute Bacterial Maxillary Sinusitis Bayer Corporation, 1998.

Subinvestigator – Long Term Safety Study of Mometasone Furoate HFA-227 Metered Dose Inhaler and Beclomethasone Dipropionate (Vanceril 84 mcg. Double Strength) in the Treatment of Asthma in Subjects Previously Maintained on Inhaled Corticosteroids – Schering – Plough Research Institute, 1998.

Subinvestigator – Glaxo SMART study SLGA 5011: A Double-Blind, Randomized, Placebo-Controlled Surveillance Study of Asthma Event Outcomes in Subjects Receiving Either Usual Pharmacotherapy of Asthma or Usual Pharmacotherapy plus Salmeterol 42 MCG (2 puffs) Twice Daily.

Subinvestigator – Byk Gulden Pharmaceutical BY 217/FK 1021: A Double-Blind, Randomized, Parallel Group Study with 125 MCG roflumilast versus 250 MCG roflumilast versus placebo in patients with asthma, 2002.

Subinvestigator - Veritas Research, Merck & Co., Inc: A Multicenter, Double-Blind, Placebo Controlled, Randomized, Parallel – Group Study to evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity, 2006.